KWM
PRME icon

Kingsview Wealth Management’s Prime Medicine PRME Stock Holding History

Kingsview Wealth Management’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.9K Sell
10,000
-25,000
-71% -$83K ﹤0.01% 1407
2026
Q1 		$122K Buy
35,000
+20,000
+133% +$76.1K ﹤0.01% 1287
2025
Q4 		$52K Sell
15,000
-9,750
-39% -$43.4K ﹤0.01% 1223
2025
Q3 		$137K Sell
24,750
-250
-1% -$1.02K ﹤0.01% 1165
2025
Q2 		$61.8K Buy
+25,000
New +$38.5K ﹤0.01% 1149

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Kingsview Wealth Management's PRME Position: Q2 2026 in Review

Kingsview Wealth Management reduced its Prime Medicine (PRME) stake by 71% in Q2 2026, selling an estimated $83K and leaving 10,000 shares worth $36.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1407.

Kingsview Wealth Management first reported a position in PRME in Q2 2025 and has held it in 5 quarters since. The position peaked at $137K in Q3 2025. 188 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Kingsview Wealth Management held 10,000 shares of Prime Medicine worth $36.9K as of Q2 2026.
  • Kingsview Wealth Management sold 25,000 Prime Medicine shares in Q2 2026, an estimated $83K.
  • Prime Medicine made up ﹤0.01% of Kingsview Wealth Management's portfolio in Q2 2026, its #1407 holding.
  • Kingsview Wealth Management first reported a position in Prime Medicine in Q2 2025 and has held it in 5 quarters since.
  • Kingsview Wealth Management's Prime Medicine position peaked at $137K in Q3 2025.
  • 188 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Kingsview Wealth Management's 13F filing for Q2 2026, filed 19 Aug 2026.